A Phase 1 Study to Assess the Pharmacokinetics of AZD9977 Administered Alone and in Combination With Itraconazole in Healthy Volunteers

A Phase 1 Single Center Open-label, Non-randomized, Fixed Sequence Study in Healthy Volunteers to Assess the Pharmacokinetics (PK) of AZD9977 When Administered Alone and With Itraconazole

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.

Study Overview

• Status: Completed
• Conditions: Heart Failure With Preserved Ejection Fraction (HFpEF)
• Intervention / Treatment: Drug: AZD9977; Drug: Itraconazole

Detailed Description

This is an open-label, non-randomized, fixed sequence study conducted at a single study center with primary aim to assess the pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole. Two types of treatments (treatment period 1 and treatment period 2) will be administered in a fixed order separated by a washout period of 3 days or more. Treatment period 1 will be single dose of AZD9977 (Dose 1) administration, in the fed state, on Day 1 followed by at least 3 days washout period. For treatment period 2, Itraconazole will be administered daily (Dose 2) from Day 4 to Day 8 plus AZD9977 (Dose 1, fed state) will be administered as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.

• Study Type: Interventional
• Enrollment (Actual): 14
• Phase: Phase 1

Contacts and Locations

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21225
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 55 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Provision of signed and dated, written informed consent prior to any study specific procedures.
2. Healthy male and female participants of non-childbearing potential aged 18 - 55 years with suitable veins for cannulation or repeated venipuncture.

3. Females must have a negative pregnancy test at screening and on admission to the unit, must not be lactating and must be of non-childbearing potential, confirmed at screening by fulfilling one of the following criteria:

   1. Postmenopausal defined as amenorrhea for at least 12 months or more following cessation of all exogenous hormonal treatments and follicle stimulating hormone (FSH) levels ≥40 mlU/ml.
   2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.
4. Have a body mass index (BMI) between 18 and 30 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive.

Exclusion Criteria:

1. History of any clinically significant disease or disorder which, in the opinion of the PI, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study..
2. History or presence of gastrointestinal, hepatic or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
3. Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the first administration of IMP.

Any clinically significant abnormalities in clinical chemistry, hematology, or urinalysis results, as judged by the PI including serum potassium > 5.0 mmol/L, serum hsTnI > 25.6 pg/mL, and NT-pro-BNP > 124 pg/mL.

5. Any clinically significant abnormal findings in vital signs as specified below and as judged by the PI at screening and on admission including:

1. Systolic blood pressure (SBP) < 90 mmHg or > 140 mmHg.
2. Diastolic blood pressure (DBP) < 50 mmHg or > 90 mmHg.

3. HR < 45 or > 90 beats per minute (bpm). 6. Any clinically significant abnormalities on 12-lead ECG, as judged by the PI.

   7. Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody, and human immunodeficiency virus (HIV) antibody.

   8. Known or suspected history of drug abuse in the last 12 months as judged by the Investigator.

   9. Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or 1 month after the last visit whichever is the longest.

   10. Plasma donation within 1 month of screening or any blood donation/loss more than 500 mL during the 3 months prior to screening.

   11. History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity, as judged by the PI or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9977.

   12. Current smokers or those who have smoked or used nicotine products (including e cigarettes) within the 3 months prior to screening.

   13. Positive screen for drugs of abuse, cotinine or alcohol at screening or on each admission to the study center.

   14. Use of drugs with enzyme-inducing properties such as St John's Wort within 3 weeks prior to the first administration of IMP.

   15. Use of any prescribed or non prescribed medication including antacids, analgesics (other than paracetamol/acetaminophen), herbal remedies, megadose vitamins (intake of 20 to 600 times the recommended daily dose) and minerals during the 2 weeks prior to the first administration of IMP or longer if the medication has a long half life.

   16. Known or suspected history of alcohol or drug abuse or excessive intake of alcohol in the last 12 months as judged by the PI.

   17. Involvement of any AstraZeneca, PAREXEL or study site employee or their close relatives.

   18. Participants who have previously received AZD9977. 19. Judgment by the PI that the participant should not participate in the study if they have any ongoing or recent (i.e., during the screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions, and requirements.

   20. Vulnerable participants , e.g., kept in detention, protected adults under guardianship, trusteeship, or committed to an institution by governmental or juridical order.

   21. Participants with any special dietary restrictions such as participants that are lactose intolerant or are vegetarians/vegans.

   22. Drugs affecting CYP3A4 (itraconazole) should be refrained from use for 3 weeks prior to study commencement and thereafter until study completion.

   23. The following exclusion criterion is driven by contraindications from the proposed concomitant CYP3A4 (itraconazole) inhibitor medications: Itraconazole (Sporanox) capsules are contra-indicated in patients with known hypersensitivity to itraconazole or to any of the excipients.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Single AZD9977; During this treatment period, healthy participants will be administered with a single AZD9977 (Dose 1) dose, in the fed state, on Day 1 followed by at least 3 days washout period.	Drug: AZD9977; Participants will receive single AZD9977 (Dose 1) capsule orally once daily in fed state, on Day 1 followed by at least 3 days washout period.
Experimental: Itraconazole + AZD9977; During this treatment period, healthy participants will be administered with Itraconazole (Dose 2) from Day 4 to Day 8 plus will be administrated with AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole will be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.	Drug: Itraconazole; Participants will receive Itraconazole daily (Dose 2) capsule orally once daily from Day 4 to Day 8 plus will be administered AZD9977 (Dose 1, fed state) as a single dose on Day 7. Dose of itraconazole has to be taken at -1 hour (1 hour prior to AZD9977 dosing) when co-administered with AZD9977.; Other Names: Sporanox

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under plasma concentration-time curve from time zero to infinity (AUC) for AZD9977	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUClast) for AZD9977	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Maximum observed plasma concentration (Cmax) for AZD9977	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time to reach Maximum Observed Plasma Concentration (tMax)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Mean residence time of the unchanged drug in the systemic circulation from time zero to infinity (MRT)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole.	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Terminal elimination rate constant (λz)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Apparent total body clearance of drug from plasmsa after extravascular administration (CL/F)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Apparent volume of distribution during the terminal phase after extravascular administration (Vz/F)	To access pharmacokinetics (PK) of AZD9977 in healthy volunteers when administered alone and in combination with multiple doses of itraconazole	Day 1 to 3: Pre-dose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose. Day 4 to 9: pre-dose on Day 7 and 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 8, 12, 16, 24, 36 and 48 hours post-dose
Number of participants with adverse events (AEs)	To assess AEs as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal blood pressure (both systolic and diastolic blood pressure)	To measure BP as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. BP will be collected after the participants has rested in the supine position for at least 5 minutes.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal pulse rate	To measure pulse rate as variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. Pulse rate will be collected after the participants has rested in the supine position for at least 5 minutes.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal 12-lead Electrocardiograms (ECG)	To examine the safety and tolerability of AZD9977 in combination with itraconazole. 12-lead safety ECG will be obtained after the participant rested in the supine position for at least 10 minutes using the sites own ECG machines. The Principal Investigator (PI) will judge the overall interpretation as normal or abnormal and this evaluation will be reported in ClinBase. If abnormal, it will be further documented as to whether or not the abnormality is clinically significant by the PI.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal physical examination findings	To assess any clinically significant abnormal physical examination findings as a variable of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. The complete physical examinations will include an assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems. The brief physical examinations will include an assessment of the general appearance, skin, abdomen, cardiovascular system and respiratory.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- White blood cell (WBC) count	To assess the white blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participnats with abnormal laboratory assessments: Hematology- Red blood cell (RBC) count	To assess the red blood cell count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of paticipants with abnormal laboratory assessments: Hematology - Hemoglobin (Hb)	To assess the Hb as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology - Hematocrit (HCT) and Reticulocyte absolute count	To assess the HCT and reticulocyte absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin (MCH)	To assess the MCH as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular volume (MCV)	To assess the MCV as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology - Mean corpuscular hemoglobin concentration (MCHC)	To assess the MCHC as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- Neutrophils absolute count	To assess the neutrophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnotmal laboratory assessments: Hematology- Lymphocytes absolute count	To assess the Lymphocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- Monocytes absolute count	To assess the Monocytes absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- Eosinophils absolute count	To assess the Eosinophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- Basophils absolute count	To assess the Basophils absolute count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Hematology- Platelets count	To assess the Platelets count as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Calcium, potassium, phosphate and sodium	To assess the serum calcium, potassium, phosphate and sodium level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Liver enzymes	To assess the serum Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Aspartate aminotransferase (AST) and Gamma glutamyl transpeptidase (GGT) level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Albumin	To assess the albumin level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - C reactive protein (CRP)	To assess the CRP level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazol	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatine kinase (CK)	To assess the CK level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Creatinine	To assess the creatinine level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Glucose (fasting)	To assess the fasting glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- Uric acid	To assess the uric acid level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry- BUN	To assess the BUN level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Total Bilirubin (TBL)	To assess the TBL level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - Indirect bilirubin	To assess the indirect bilirubin as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - High-sensitivity troponin I ((hsTnI)	To assess the High-sensitivity troponin I ((hsTnI) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Serum Clinical chemistry - N-terminal-pro-brain natriuretic peptide (NT-pro-BNP)	To assess the N-terminal-pro-brain natriuretic peptide (NT-pro-BNP) as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Protein	To assess the urine protein level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for protein, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Blood	To assess the urine blood level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole. If urinalysis is positive for blood, a microscopy test will be performed to assess RBC, WBC, casts [cellular, granular, hyaline]).	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)
Number of participants with abnormal laboratory assessments: Clinical Urinalysis - Glucose	To assess the urine glucose level as variables of safety and tolerability after administration of single dose of AZD9977 in combination with itraconazole.	From screening (Day -28) till follow-up visit (up to approximately 6 weeks)

Collaborators and Investigators

• Sponsor: AstraZeneca
• Investigators: Principal Investigator: Ronald Goldwater, Dr.

Study record dates

Study Major Dates

• Study Start (Actual): February 22, 2019
• Primary Completion (Actual): April 1, 2019
• Study Completion (Actual): April 1, 2019

Study Registration Dates

• First Submitted: February 14, 2019
• First Submitted That Met QC Criteria: February 14, 2019
• First Posted (Actual): February 15, 2019

Study Record Updates

• Last Update Posted (Actual): April 22, 2019
• Last Update Submitted That Met QC Criteria: April 19, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: Healthy volunteers; Pharmacokinetics; Itraconazole; Drug-drug interaction; Congestive heart failure; Open-label non-randomized
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Heart Failure; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Anti-Infective Agents; Enzyme Inhibitors; Hormones, Hormone Substitutes, and Hormone Antagonists; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Hormone Antagonists; Antifungal Agents; Steroid Synthesis Inhibitors; 14-alpha Demethylase Inhibitors; Itraconazole
• Other Study ID Numbers: D6401C00003

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes